No abstract available
Keywords:
ALK secondary mutation; EML4-ALK; Longitudinal monitoring; Resistance mutation; Target sequencing.
MeSH terms
-
Aged
-
Aminopyridines
-
Anaplastic Lymphoma Kinase / antagonists & inhibitors
-
Anaplastic Lymphoma Kinase / genetics*
-
Antineoplastic Agents / therapeutic use*
-
Carcinogenesis / genetics
-
Carcinoma, Non-Small-Cell Lung / diagnosis*
-
Carcinoma, Non-Small-Cell Lung / genetics
-
Circulating Tumor DNA / analysis
-
Crizotinib / therapeutic use
-
Drug Resistance, Neoplasm
-
Humans
-
Lactams
-
Lactams, Macrocyclic / therapeutic use
-
Liquid Biopsy
-
Lung Neoplasms / diagnosis*
-
Lung Neoplasms / genetics
-
Male
-
Mutation / genetics*
-
Neoplasm Staging
-
Oncogene Proteins, Fusion / genetics*
-
Organophosphorus Compounds / therapeutic use
-
Protein Kinase Inhibitors / therapeutic use*
-
Pyrazoles
-
Pyrimidines / therapeutic use
Substances
-
Aminopyridines
-
Antineoplastic Agents
-
Circulating Tumor DNA
-
EML4-ALK fusion protein, human
-
Lactams
-
Lactams, Macrocyclic
-
Oncogene Proteins, Fusion
-
Organophosphorus Compounds
-
Protein Kinase Inhibitors
-
Pyrazoles
-
Pyrimidines
-
Crizotinib
-
Anaplastic Lymphoma Kinase
-
brigatinib
-
lorlatinib